CAMBRIDGE, Mass., Aug 24, 1998 (Reuters) - Vertex Pharmaceuticals Inc
said Monday it signed an agreement with Schering AG that could be worth
$88 million to collaborate on the research, development and
commercialization of orally active neurophilin compounds to promote
nerve regeneration for the treatment of neurological diseases.
Neurophilin compounds may play a future role in the treatment of a range
of diseases, including peripheral neuropathies, PARKINSON'S disease, and
spinal cord injury, Vertex said.
The company's neurophilin compounds have been shown to accelerate
functional recovery and promote nerve growth in several different animal
models of central and peripheral nervous system injury.
<snip>
Copyright © 1998 Reuters Limited.
--
Judith Richards, London, Ontario, Canada
[log in to unmask]
^^^
\ /
\ | / Today’s Research
\\ | // ...Tomorrow’s Cure
\ | /
\|/
```````
